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Recurrent somatic mutation in DROSHA induces
microRNA profile changes in Wilms tumour
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Wilms tumour (WT) is an embryonal kidney neoplasia for which very few driver genes have
been identified. Here we identify DROSHA mutations in 12% of WT samples (26/222) using
whole-exome sequencing and targeted sequencing of 10 microRNA (miRNA)-processing
genes. A recurrent mutation (E1147K) affecting a metal-binding residue of the RNase IIIb
domain is detected in 81% of the DROSHA-mutated tumours. In addition, we identify non-
recurrent mutations in other genes of this pathway (DGCR8, DICER1, XPO5 and TARBP2).
By assessing the miRNA expression pattern of the DROSHA-E1147K-mutated tumours and
cell lines expressing this mutation, we determine that this variant leads to a predominant
downregulation of a subset of miRNAs. We confirm that the downregulation occurs
exclusively in mature miRNAs and not in primary miRNA transcripts, suggesting that the
DROSHA E1147K mutation affects processing of primary miRNAs. Our data underscore the
pivotal role of the miRNA biogenesis pathway in WT tumorigenesis, particularly the major
miRNA-processing gene DROSHA.
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W
ilms tumour (WT) is an embryonal kidney neoplasia
that, despite a generally good prognosis, is associated
with relapse in up to 15% of cases, requiring additional
treatment and leading to adverse long-term effects1,2. WT affects
1/10,000 children worldwide3,4 and is the most common pediatric
kidney cancer. Approximately 10% of WT cases are associated
with germline mutations and/or congenital abnormalities,
such as those caused by WT1 mutations/deletions (WAGR
and Denys–Drash syndromes), 11p15 duplications/imprinting
deregulation (Beckwith–Wiedemann syndrome), DIS3L2
mutations (Perlman syndrome), BRCA2 biallelic mutations
and the recently described DICER1 mutation in familial
pleuropulmonary blastoma syndrome5–10.
A few genes have been identified as somatically mutated in
WT, the most frequent being WT1, CTNNB1 and WTX, which
together account for B30% of WT cases11–15. Alterations
affecting TP53, DIS3L2, FBXW7, MYCN and DICER1 are also
occasionally reported8,16–18. However, up to 70% of WTs are not
associated with an identified somatic mutation, and there is an
urgent need to uncover additional mutated pathways for targeting
by specific therapeutic agents.
In this study, we use whole-exome sequencing (WES) and
targeted sequencing of core genes of the microRNA (miRNA)
biogenesis pathway to identify somatic mutations in WT. We
reveal that DROSHA mutations occur in 12% of WT samples
(26/222)—the majority of them in a recurrent hotspot (E1147K);
moreover, we identify unique truncating and missense mutations
in other miRNA-processing genes (DGCR8, DICER1, XPO5 and
TARBP2). In addition, we evaluate the miRNA expression pattern
of DROSHA-E1147K-mutated tumours and cell lines expressing
this mutated protein and determine that the E1147K mutation
leads to changes in the miRNA profile, predominantly causing
downregulation of a subset of mature miRNAs. Our results
provide evidence that DROSHA and the miRNA biogenesis
pathway may have a crucial role in WT tumorigenesis.
Results
Identification of DROSHA mutations. To identify somatic
mutations possibly associated with WT tumorigenesis, we per-
formed WES of four samples of a family trio, which included
tumour and blood samples from a sporadic WT patient and blood
samples from his unaffected parents. The on-target mean
coverage was 67 , and the percentage of bases covered at least
20 ranged from 48.3 to 73.4% (Supplementary Table 1). We
identified a total of 10 unknown coding somatic variants (5 single
nucleotide variants (SNVs) and 5 indel) (Supplementary Table 2).
This low rate of somatic alterations was somewhat expected
because, in general, embryonal tumours appear to contain few
somatic mutations19. Of the five identified missense SNVs, only
the c.3439G4A (p.E1147K) variant of DROSHA was validated by
Sanger sequencing as a somatic mutation that was not present in
the blood of the WT patient or his parents (the remaining four
variants were not confirmed).
DROSHA encodes a nuclear RNase III protein that plays a
central role in the miRNA biogenesis pathway. Drosha acts by
cleaving primary miRNAs (pri-miRNAs) to release hairpin-
shaped pre-miRNAs that are subsequently cut by the cytoplasmic
RNase III Dicer to generate mature miRNAs20. Drosha possesses
two RNase III domains, named RIIIa and RIIIb, which form an
intramolecular dimer that cleaves the 30 and 50 strands of the
stem, respectively21,22. The DROSHA E1147K mutation identified
in this study is a residue of the RIIIb domain that is part
of the signature motif of RNase III proteins21 and that is
conserved throughout prokaryotes and eukaryotes (Fig. 1a). The
affected amino acid is one of four acidic residues that form a
metal-binding (Mg2þ ) cluster at the center of the RNase III
catalytic site and thus is essential for catalytic activity21.
Mutational studies of the Escherichia coli RNASEN protein
have demonstrated that amino-acid substitutions of the
equivalent residue (E41A in the E. coli protein) abolish the
cleavage function of the protein in a Mg2þ concentration-
dependent manner by decreasing the affinity of the protein for
metal23. The DROSHA E1147K mutation identified in WT leads
to the substitution of a negatively charged amino acid (glutamic
acid) to a positively charged one (lysine), likely interfering with
metal binding at this position.
To determine whether the DROSHA E1147K mutation is a
recurrent event in WTs, we sequenced the RNase IIIb domain of
139 favourable histology WT samples of all types (14 frozen and
125 formalin-fixed paraffin-embedded (FFPE) tissues) from our
Institution (A. C. Camargo Cancer Center—ACC) and 82 frozen
favourable histology WT samples, enriched for WTs stages III
and IV with a predominant blastema component, obtained from
the Children’s Oncology Group (COG) (the clinical features of
these cohorts are provided in Supplementary Table 3). In
addition, we sequenced the entire RIIIa and RIIIb domains of
96 fresh-frozen samples from both cohorts.
Overall, B10% of WTs harboured DROSHA mutations in the
investigated domains: 16/140 tumours (11%) from ACC (includ-
ing the index case) and 8/82 tumours (10%) from COG. The
E1147K mutation identified in the index case was a recurrent
mutation that was encountered in 20 additional WTs, thus
representing 87% (21/24) of DROSHA mutations in the RNase
IIIa and b domains. The other three affected patients were
positive for a missense mutation in another metal-binding residue
of RIIIb (c.3452A4G; p.D1151G—affecting two patients) and a
mutation at a residue involved in intramolecular dimeriza-
tion21,24 of the RIIIa domain (c.2977G4A; p.E993K—affecting
one patient) (Fig. 1a,b). Interestingly, all E1147K and D1151G
mutations were heterozygous, whereas the E993K alteration was a
homozygous alteration (Fig. 1c) (the likely presence of two
mutated alleles was detected by array-comparative genomic
hybridization (aCGH) and duplex quantitative PCR (qPCR)25—
Supplementary Fig. 1).
Recently, somatic mutations in another miRNA-processing
enzyme, Dicer, were identified in WT and other tumours of
embryonal/primitive origin (ovarian sex cord–stromal and
testicular germ-cell tumours and rhabdomyosarcomas)18,26.
Remarkably, the DICER1 mutations clustered around the four
critical metal-binding residues in the RIIIa and, more frequently,
RIIIb domain, similar to our findings in DROSHA. To determine
whether DROSHA mutations were also present in other
embryonal tumours, we sequenced the RNase IIIb domain
of 44 samples of 6 different types of embryonal tumours
(2 esthesioneuroblastomas, 9 hepatoblastomas, 12 rhabdomyo-
sarcomas and 21 neuroblastic tumours), but no DROSHA
mutations were detected in this domain. We also screened 83
adult kidney tumours and did not detect any mutations in this
domain (Fig. 1b).
Targeted sequencing of miRNA-processing genes. To investi-
gate the occurrence of mutations in core components of the
miRNA-processing pathway in WT, we performed targeted
parallel sequencing of 10 genes from this pathway (DROSHA,
DGCR8, DICER1, RAN, XPO5, TARBP2, AGO1, AGO2, GEMIN4
and DDX20). To generate a detailed spectrum of somatic muta-
tions in WT, we also included in this targeted sequencing panel 6
genes previously described as mutated in WT (WT1, CTNNB1,
WTX, TP53, DIS3L2 and FBXW7 8,11–18. We evaluated a total of
66 frozen WT samples (15 from ACC and 51 from COG).
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Figure 2a presents the mutational spectrum of the genes that
harboured any point mutations as well as genomic imbalances
detected within these genes by aCGH.
Point mutations were identified in five miRNA-processing
genes (DROSHA, DGCR8, DICER1, XPO5 and TARBP2) and in
all 6 genes previously associated with WT (WT1, CTNNB1, WTX,
TP53, DIS3L2 and FBXW7). Descriptions of the variants and the
clinical data for the patients with mutations are provided in
Table 1 and Supplementary Tables 4 and 5. Interestingly, in 33%
(22/66) of WTs, we detected potentially deleterious mutations in
genes of the miRNA-processing pathway, while genes previously
described to be mutated in WT were detected in 22.7% (15/66) of
WTs. We considered as possibly disease-associated all indels,
nonsense and splice site mutations, and missense alterations
classified as damaging by at least one of the prediction software
used (Fig. 2a; Table 1). The substantial frequency of mutations in
genes involved in miRNA biogenesis suggests that impaired
miRNA maturation might play a pivotal role in WT.
Among the miRNA-processing genes, DROSHA was most
frequently mutated. In addition to the missense mutations
previously identified by sequencing the RIIIa and b domains,
one missense (c.631C4A; p.P211T) and two novel nonsense
mutations (c.136C4T; p.Q46* and c.1240C4T; p.R414*) were
identified in this gene. Both nonsense mutations were present
in the same patient (COG_1108—Fig. 2b). Sequencing of
allele-specific PCR products amplified from complementary
DNA (cDNA) confirmed that each mutation is present in one
allele (biallelic mutations) (Supplementary Fig. 2); however, the
unavailability of normal tissue from this patient prevented the
determination of the nature (somatic or germline) of both
mutations. In summary, a total of 6 distinct DROSHA pathogenic
mutations were identified in 26 WT samples (Supplementary
Table 6). Remarkably, we detected an overlap between the
DROSHA point mutations and WT1 genomic losses. Of 10
patients harbouring DROSHA mutations, four also presented loss
of the WT1 gene (40%), while the rate of WT1 loss in the whole
series was 9% (6/66) (Fig. 2a; Supplementary Table 4).
We also identified deleterious frameshift mutations in two
other miRNA-processing genes: DGCR8 (p.R32fs) and TARBP2
(p.R353fs). DGCR8 together with Drosha forms the micro-
processor unit responsible for cleaving pri-miRNAs into pre-
miRNAs22,27, while TRBP (encoded by TARBP2), together with
Dicer, forms the complex necessary for converting pre-miRNAs
into mature miRNAs28. Remarkably, the patient presenting the
frameshift duplication in DGCR8 also harboured a heterozygous
loss of the entire chromosome 22, where this gene is located,
leading to the deletion of the normal allele (Fig. 2c). In addition,
non-recurrent missense mutations were identified in DGCR8
(G55S, S92R, E518K, A558T and Y721H), DICER1 (Q48E, I85M
and D1810N), XPO5 (V832I) and TARBP2 (R296H). With the
Cohort Diagnosis No ofcases
No DROSHA
mutations
Mutation
type
ACC Wilms tumour 140 16 (11.4%) E1147KD1151G
COG Wilms tumour 82 8 (9.7%) E993KE1147K
ccRCC Adult clear cell renalcell carcinoma 83 0 (0%) –
ET Diverse embryonal tumours 44 0 (0%) –
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Figure 1 | DROSHA mutations identified in WTs. (a) Schematic representation of the Drosha protein, showing the position of the three identified
mutations in the catalytic RNase III domains (RIIIa and RIIIb). Red circles denote the absolute frequency of each mutation in the entire WT cohort
(222 patients). In the magnified region, the missense mutations E993K (RIIIa), E1147K (RIIIb) and D1151G (RIIIb) are shown in the context of RNase III
domain conservation across several species; conserved residues are shaded in pink (80% conservation), while invariant residues are in red. The lower
bar represents the 9-amino-acid signature motif of RNase III proteins. Domain abbreviations: Pro-rich, proline-rich region; RS-rich, serine/arginine-rich
region; RIIIa, RNase IIIa domain; RIIIb, RNase IIIb domain; dsRBD, double-stranded RNA-binding domain. (b) Frequency of DROSHA mutations (RIIIa and/or
RIIIb domains) in the four series of tumours. We investigated two independent WT cohorts (140 from A. C. Camargo (ACC) (including the index case)
and 82 from the Children’s Oncology Group (COG)), a group of 83 adult clear-cell renal cell carcinomas (ccRCC), and 44 embryonal tumours from
different organs (ET). Mutations in the RIIIa and RIIIb domains of DROSHA were detected in B11% (24/222) of WTs. (c) Sequence traces from DNA
(top panels) and cDNA (bottom panels) of DROSHA-mutated WTs. All tumours harbouring either the E1147K (n¼ 21) or D1151G (n¼ 2) mutation
presented the variant in a heterozygous state (DNA and/or RNA data); by contrast, the E993K alteration, which was detected in only one patient,
was a homozygous mutation (both tumour DNA and RNA samples). NA, RNA not available.
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exception of the DICER1 D1810N variant located in the RIIIb
domain, which was previously described as a driver mutation in
other tumour types26, the true significance of the remaining
missense alterations in WT onset has yet to be revealed.
Analysis of miRNA expression profiles. The most frequently
occurring mutation identified in our study was the DROSHA
E1147K mutation (21/222 samples). To elucidate the influence of
this mutation on the miRNA maturation process, we compared
the mature miRNA expression profile of six DROSHA-E1147K
WT samples with six wild-type WTs (without mutations in
the miRNA core genes) using a TaqMan Array platform
(Supplementary Table 7). Unsupervised assessment of global
miRNA expression by principal component analysis revealed that
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Figure 2 | Mutation spectrum of WTs. (a) Mutations of the miRNA core processing genes (miRNA biogenesis) and WT-associated genes (WT
associated) in 66 fresh-frozen WT samples. Only the genes that were affected by point mutations in at least one sample are shown. Point mutations and
indels (left panels) were identified by targeted parallel sequencing, and genomic imbalances (right panels) were detected by aCGH. aCGH data were
obtained for 53 samples (2 from ACC and 51 from COG) from a previous study of the group. The coloured squares refer to the corresponding type of point
mutation (missense, splice site, frameshift indel, in-frame indel and nonsense) or genomic imbalance (loss and gain). A detailed description of each
mutation is provided in Table 1; Supplementary Tables 4 and 5. (b) DROSHA nonsense mutations (c.136C4T; p.Q46* and c.1240C4T; p.R414*) identified in
a single patient (COG_1108) by targeted parallel sequencing (upper panels) and validated by capillary Sanger sequencing (bottom panels). (c) Mutations
identified in the DGCR8 gene. The first panel depicts the 11-nt frameshift duplication identified by targeted parallel sequencing. The middle panel presents
the validation by capillary sequencing and the translation of the mutated allele, highlighting the formation of a premature stop codon 62 nt downstream of
the alteration. This patient (COG_4057) also presented a heterozygous loss of the entire chromosome 22 (aCGH profile—bottom panel), leading to the
deletion of the wild-type DGCR8 allele. Owing to tumour heterogeneity and/or normal cell contamination, this aneuploidy is present in mosaic, resulting in
B30% of reads from Ion Torrent sequencing displaying the wild-type allele and in a log2 ratio value of 0.4 in aCGH analysis.
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DROSHA-mutated and non-mutated tumours were perfectly
discriminated (Supplementary Fig. 3), revealing a strong rela-
tionship between the miRNA profile and the presence of the
E1147K mutation. Next, we compared the expression levels of
miRNAs between the two groups. A total of 64 mature miRNAs
were differentially expressed in E1147K-mutated tumour samples
compared with wild-type WT, with a predominance of reduced
miRNA expression, as 59 miRNAs were downregulated and
only 5 were upregulated (fold change Z|2|; false discovery rate
(FDR)-corrected Pr0.05) (Fig. 3a; Supplementary Table 8). For
the 21 miRNAs presenting 5p- and 3p-derived miRNAs in
the assay (7 differentially expressed and 15 non-differentially
expressed), concordant expression data were detected for both 5p
and 3p mature miRNAs (Supplementary Table 9), underscored
by similar fold changes for 5p and 3p paired miRNAs. This
suggests that in contrast to what is observed for DICER1 muta-
tions affecting the RIIIb domain, which result in a complete
absence of 5p-derived miRNAs but have no effect on 3p-derived
specimens29, the DROSHA E1147K mutation affects miRNAs
derived from both strands.
The 64 differentially expressed miRNAs affected by the
DROSHA E1147K mutation were used for unsupervised
hierarchical clustering of the six E1147K-mutated tumours
and six controls (wild-type for the miRNA core genes). The
resulting cluster completely discriminated E1147K-mutated from
non-mutated WT samples (Fig. 3b). Moreover, we also
interrogated the expression profile of this set of miRNAs in three
additional WT samples with other mutations in the DROSHA or
DGCR8 genes (COG_1110: DROSHA homozygous E993K;
COG_1108: two nonsense mutations in DROSHA—Q46* and
R414*; and COG_4057: DGCR8 frameshift and genomic loss).
Interestingly, the two tumours with double hits (COG_1108 and
COG_4057) exhibited remarkably lower expression of the
affected miRNAs (Supplementary Fig. 4).
Table 1 | Classification of point mutations detected in 66 frozen WT samples.
ID Gene ID Protein change Variant type dbSNP NHLBI ESP Polyphen2 SIFT Mutation
Taster
Final
classification
ACC_8 DROSHA p.E1147K Missense PD D DC PDA
TP53 p.P72A Missense B T P B
FBXW7 p.R35C Missense PD D DC PDA
COG_4181 DROSHA p.E1147K Missense PD D DC PDA
COG_1124 DROSHA p.E1147K Missense PD D DC PDA
COG_970 DROSHA p.E1147K Missense PD D DC PDA
COG_1144 DROSHA p.E1147K Missense PD D DC PDA
ACC_12 DROSHA p.E1147K Missense PD D DC PDA
COG_128 DROSHA p.E1147K Missense PD D DC PDA
COG_1110 DROSHA p.E993K Missense PD D DC PDA
COG_526 DROSHA p.P211T Missense rs202227062 T¼ 1; G¼ 12127 B D P PDA
COG_1108 DROSHA p.Q46* Nonsense PDA
DROSHA p.R414* Nonsense PDA
#ACCp_84 DROSHA p.D1151G Missense PD D DC PDA
#ACCp_151 DROSHA p.D1151G Missense PD D DC PDA
COG_032 DGCR8 p.E518K Missense PD D DC PDA
FBXW7 p.E117del In-frame del PDA
COG_353 DGCR8 p.Y721H Missense POD T DC PDA
COG_219 DGCR8 p.S92R Missense rs201435288 A¼ 1; T¼ 13005 B D DC PDA
COG_4159 DGCR8 p.A558T Missense B D DC PDA
ACC_15 DGCR8 p.G55S Missense PD D DC PDA
COG_4057 DGCR8 p.R32fs Frameshift dup PDA
COG_117 DICER1 p.I85M Missense B T DC PDA
WT1 p.P183fs Frameshift ins PDA
CTNNB1 p.Y333F Missense PD D DC PDA
ACC_13 DICER1 p.D1810N Missense PD D DC PDA
COG_396 DICER1 p.Q48E Missense PD T DC PDA
ACC_4 XPO5 p.V832I Missense B T P B
TARBP2 p.R296H Missense B T P B
COG_2050 TARBP2 p.R353fs Frameshift del PDA
ACC_5 WT1 p.D367_splice Splice site PDA
CTNNB1 p.T41A Missense rs121913412 ND POD D DC PDA
ACC_7 CTNNB1 p.N387K Missense PD D DC PDA
ACC_1 CTNNB1 p.S45F Missense rs121913409 ND PD D DC PDA
COG_2081 CTNNB1 p.S45P Missense rs121913407 ND PD D DC PDA
COG_6000 WT1 p.K316fs Frameshift ins PDA
WT1 p.F391fs Frameshift Iins PDA
COG_1290 WT1 p.V379fs Frameshift del PDA
COG_031 WTX p.D354fs Frameshift del PDA
COG_4135 WTX p.R353* Nonsense rs137852216 ND PDA
COG_1065 WTX p.R497* Nonsense PDA
ACC_10 TP53 p.339_340EM4V In-frame del PDA
COG_497 DIS3L2 p.Q230* Nonsense PDA
COG_4196 DIS3L2 p.R483G Missense PD D DC PDA
B, benign; D, damaging; DC, disease causing; P, polymorphism; PD, probably damaging; PDA, possibly disease-associated; POD, possibly damaging; T, tolerated; WT, Wilms tumour.
NHLBI ESP, NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/)—the absolute frequency of the variant allele followed by the reference allele are shown; ND, No variant was detected in this
region in this database.
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Figure 3 | Comparison of miRNA expression levels of six DROSHA-E1147K-mutated and six wild-type WT samples. The samples used in this analysis
were fresh-frozen tumours from COG from patients that were not subjected to neoadjuvant chemotherapy. Panels a and b refer to the TaqMan Array
miRNA profiling experiment. Panel c refers to the individual TaqMan assays. (a) Volcano plot showing a predominant reduction in mature miRNAs in
DROSHA-E1147K tumours. The x axis represents the difference of group means (log2 expression values) of DROSHA-mutated and wild-type tumours; the y
axis represents the statistical significance ( log10 P-values). Each miRNA is represented by a dot, and red dots represent those miRNAs that were
differentially expressed between the groups; red dots with black borders were selected for pri-miRNA/mature miRNA validation (Fig. 3c). A total of 64 out
of 249 miRNAs were differentially expressed between mutated and non-mutated samples. Downregulated miRNAs were over-represented, as 59 miRNAs
were downregulated and only 5 were upregulated (Supplementary Table 8). (b) Unsupervised hierarchical clustering analysis based on expression data for
the 64 differentially expressed miRNAs confidently discriminated DROSHA-E1147K from non-mutated samples. (c) Primary and mature miRNA expression.
The expression of primary and mature miRNA pairs of eight differentially expressed (DE) and six non-differentially expressed controls (non-DE) was
assessed by TaqMan individual assays of the same 12 samples from the array platform. Mean values and s.d. of experiments are shown; statistical
significance was calculated using the t-test (*Pr0.01; **Pr0.001; ***Pr0.0001). While all eight DE mature miRNAs were validated as differentially
expressed between the DROSHA-mutated and wild-type groups (bottom diagrams), none of the eight DE pri-miRNAs exhibited any significant difference in
expression (top diagrams). For the six control miRNAs, no difference in expression level was observed in both mature and pri-miRNAs between the groups
(fold changes and P-values are presented in Supplementary Table 9). These results confirm that the differences in mature miRNA expression levels resulted
from impaired Drosha activity.
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To determine whether these differences in mature miRNA
quantities resulted from impaired activity of DROSHA E1147K in
cleaving pri-miRNAs, we evaluated the expression of pri-miRNAs
and their matching mature miRNAs (Fig. 3c; Supplementary
Table 10). We selected 8 miRNAs from the 64 miRNAs that were
differentially expressed between mutated and non-mutated
tumours and six of the 185 miRNAs that did not exhibit
significant differences in expression as negative controls. As
expected, none of the eight selected pri-miRNA transcripts were
significantly differentially expressed between the DROSHA-
E1147K and wild-type groups, suggesting no alteration in terms
of the transcriptional regulation of these transcripts. By contrast,
the differential expression of the corresponding mature miRNAs
between the two groups was confirmed, suggesting that
these differences were indeed a consequence of defective
Drosha processing. No differences in the expression levels of
the six miRNAs used as negative controls, whether mature or
pri-miRNAs, were observed between the DROSHA-E1147K and
wild-type groups.
In vitro effects of E1147K DROSHA mutation. Next, we used a
controlled cell line assay to evaluate the effects of the E1147K
mutation on miRNA regulation. We assessed the miRNA
expression profile of HEK293 cells transiently transfected with
wild-type or E1147K-DROSHA plasmids in a time course
experiment to monitor changes in miRNA expression over time.
The time course experiment was designed to permit the
repopulation of miRNA by action of the mutated protein in the
processing of pri-miRNAs to mature specimens. Consistent with
our observations in the tumour cohort, E1147K-transfected cells
exhibited a significant reduction in mature miRNA levels over
time compared with both wild-type DROSHA and mock-
transfected cells (Fig. 4a; Supplementary Figs 5 and 6).
Furthermore, 31/59 miRNAs that were downregulated in the
DROSHA-mutated tumours also exhibited decreased expression
in E1147K-HEK293 transient cells (Supplementary Table 11).
To further validate the effects of the E1147K mutation, we
simulated in vitro the heterozygous expression of the mutation
observed in the tumours by stably transfecting HEK293T cells
with wild-type or E1147K-DROSHA. Stable transfection resulted
in reduced expression of the exogenous gene, and cDNA
sequencing revealed that both the mutated and endogenous
wild-type alleles were expressed in similar levels (Fig. 4b;
Supplementary Fig. 7). Analysis of the miRNA expression profiles
demonstrated that E1147K-stably transfected cells also presented
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Figure 4 | miRNA profile in cell line models expressing E1147K Drosha. (a) Time course experiment of miRNA expression in HEK293 cells transiently
expressing wild-type or E1147K Drosha. A schematic representation of the experiment is depicted in the top panel: transfections were performed twice in a
72-h interval (1st trans and 2nd trans), and miRNA expression levels were measured at three time points using the TaqMan Array platform (T1, T2 and T3).
The middle panel represents the Short Time-series Expression Miner (STEM) analysis profiles, which were used to cluster and analyse the expression data.
Of the six considered profiles produced by STEM analysis (Supplementary Fig. 6), E1147K-transfected cells presented two statistically significant profiles—
(profile 1: P¼ 2 10 16; and profile 2: P¼ 2 10 8) that harboured more genes than expected by chance (48 and 54 genes, respectively). These two
profiles represent a reduction in mature miRNA levels from time points T1 to T3. ****Pr0.00001. NS, not significant. (b) miRNA expression in HEK293T
cells stably transfected with wild-type or E1147K Drosha. The top panel depicts a schematic representation of the experiment, showing the time length of
selection and the passages at which cell extracts were collected for miRNA expression analysis. Four passages of each stable cell line were evaluated for
miRNA expression using the TaqMan Array platform, and the mean expression values of each miRNA in E1147K and wild-type cells were compared. The
middle panel presents the cDNA sequencing traces, which demonstrate that stable transfection resulted in similar expression levels of the mutant and
endogenous wild-type alleles. The lower panel displays a volcano plot showing a trend to preferential reduction in mature miRNAs in E1147K-stably
transfected cells, characterized by the enrichment of miRNAs species in the left side of the volcano plot. The x axis represents the log2 fold change between
HEK293T-E1147K and wild-type cells; the y axis represents the statistical significance ( log10 P-values).
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a trend to preferential reduction in mature miRNA levels
compared with wild-type DROSHA, as demonstrated by the
enrichment of miRNAs species in the left side of the volcano plot
(Fig. 4b). However, as expected, the miRNA downregulation was
surely less robust than that observed in tumours or the transient
transfection assay, since by using the same arbitrary stringent
criteria applied for the tumours (fold change Z|2|; FDR-
corrected Pr0.05) no miRNAs could be classified as differentially
expressed between E1147K-stably transfected cells and wild-type.
Discussion
In this study, we identified and characterized the effects of
recurrent DROSHA E1147K mutations in WTs. Overall, our data
suggest that the predominant effect of DROSHA mutations is the
reduction in mature miRNA expression. Drosha and Dicer
function in a stepwise manner to generate mature miRNAs.
Mutations that abolish the cleavage function of one domain of
RNase III proteins with two RIII domains, such as Drosha and
Dicer, do not affect the cleavage of the other domain,
consequently leading to the formation of incompletely processed
RNA substrates22,30. Given that Dicer most efficiently cuts pre-
miRNAs presenting the canonical structure of a two-nucleotide 30
overhang31, the double-stranded RNA structures derived from
the defective processing of a mutated Drosha would most likely
be unrecognizable by Dicer. Thus, given that amino-acid
substitutions in any of the four critical metal-binding residues
of Drosha, such as the E1147K mutation, abolish the RNase III
catalytic activity of the affected domain, and based on the data
observed in our study, we can suggest that pri-miRNAs are
incompletely cleaved by the E1147K mutant Drosha, thereby
impairing Dicer recognition and ultimately leading to a decreased
amount of mature miRNA molecules.
We and others have demonstrated that nephrogenesis
and Wilms tumorigenesis share gene expression regulation
patterns32–35. Furthermore, repression of miRNA maturation
through inhibition of DROSHA and DICER1 expression impairs
accurate kidney differentiation36–38 and promotes tumorigenesis
in several cell lines39. In this context, we speculate that the
reduction in mature miRNAs caused by DROSHA E1147K
mutations might impair kidney differentiation and contribute to
WT onset.
In summary, we have demonstrated that the DROSHA E1147K
is a recurrent mutation and that DROSHA and other miRNA-
processing genes are mutated in about 33% (22/66) of WT
samples, implying that defective miRNA biogenesis may
contribute to WT development. However, as the COG cohort
displays WT samples of predominant blastemal histology, the
frequency of mutations in this pathway in a broad unbiased WT
series still remains to be determined. Our findings, together with
the recent discovery of DICER1 mutations in other tumours18,26,
reveal that mutations disrupting the miRNA-processing
machinery represent key events in embryonal tumorigenesis.
These insights open a new field of investigation into these
neoplasias and highlight this pathway as a putative target for drug
development and cancer therapy.
Methods
Samples. Four samples from a family trio were subjected to WES: tumour and
blood from one patient (ID¼ACC_12) affected by a favourable-histology WT
(wild type for WT1 gene) and blood from the unaffected parents. For DROSHA
mutation screening, 139 WT samples were retrieved from the Biobank and archives
of A. C. Camargo Cancer Center (14 fresh-frozen samples and 125 FFPE samples).
The validation cohort comprised 82 WT samples from patients enrolled in the
National Wilms Tumour Study (NWTS-5—USA) from the COG (these samples
are enriched for WTs stages III and IV with a predominant blastema component,
which were selected for a previous gene expression study of our group40). Clinical
features of these WT cohorts are described in Supplementary Table 3. In addition,
44 fresh-frozen samples of six different types of embryonal tumours
(2 esthesioneuroblastomas, 9 hepatoblastomas, 12 rhabdomyosarcomas and
21 neuroblastic tumours) and 83 adult kidney tumours (clear-cell renal cell
carcinoma) were retrieved from the biobank of A. C. Camargo Cancer Center and
were screened for DROSHA mutations.
For miRNA global expression evaluation, only RNA from fresh-frozen samples
that were not submitted to chemotherapy before surgery was used (samples from
COG) (clinical features of samples used in this analysis are described in
Supplementary Table 5). aCGH data were obtained from a previous study of the
group (Krepischi et al., unpublished data) that investigated genomic gains and
losses in a subset of the fresh-frozen samples (2 from ACC and 51 from COG).
All samples were obtained with informed consent. This work was conducted in
accordance with the principles of the Declaration of Helsinki and was approved by
the A. C. Camargo Cancer Center ethics committee under number CEP 764/06.
DNA and RNA isolation. Genomic DNA and RNA samples were obtained from
the DNA and RNA laboratory of A. C. Camargo Biobank. DNA from blood
samples was purified using the Puregene Genomic DNA Isolation Kit (Gentra
Systems), according to the manufacturer’s instructions. Genomic DNA was
obtained from fresh-frozen or FFPE tumours using a phenol:chlorophorm method.
RNA was isolated from frozen tumour tissue (10–100mg) or cell pellets (106 cells)
using TRIzol (Invitrogen) and Precellys 24 tissue homogenizer (Bertin Technolo-
gies). DNA and RNA concentration, purity and integrity were assessed by spec-
trophotometry (Nanodrop 2000) and microfluidics-based electrophoresis (Agilent
2100 Bioanalyzer), respectively. Supplementary Table 5 presents the RNA integrity
(RIN) data of samples used in miRNA and mRNA array experiments.
WES. WES was performed using the SureSelect 50Mb All Exons kit (Agilent
Technologies), followed by sequencing of 110 base pairs of paired-end libraries in a
Solid 5500XL System (Life Technologies). The resulting sequences were mapped to
the reference genome (GRCh37/hg19) obtained from UCSC Genome Browser
(http://genome.ucsc.edu) with Bioscope (http://www.lifescopecloud.com/) and
NovoalignCS (http://novocraft.com/). Sequence variants (SNVs and indels) were
identified with SAMtools (http://samtools.sourceforge.net/) and the mpileup
(http://samtools.sourceforge.net/mpileup.shtml) and annotated if present on
dbSNP (release #137) or COSMIC v60. Next, the identified variants were
considered as possible candidates if base coverage wasZ10 and variant base was
present in at least 15% of the reads, and was not reported in dbSNP.
Sanger sequencing and pyrosequencing. Fresh-frozen tumours were screened by
Sanger sequencing of either genomic DNA or cDNA, while FFPE samples were
screened by pyrosequencing of genomic DNA. Sanger PCR was performed with
GoTaq Green Master Mix (Promega), purified with ExoSAP-IT (USB Corporation)
and sequenced in both directions using an ABI 3130xl DNA sequencer (Life
Technologies). The resulting sequences were aligned using CLCBio Genomics
Workbench Software (CLCBio). Pyrosequencing PCR was performed with a
PyroMark PCR kit (Qiagen), and the PCR products were sequenced according to
the manufacturer’s protocol with a PyroMark Q96 ID instrument (Qiagen). The
primer sequences used in these analyses are described in Supplementary Table 12.
Mutations identified by Sanger and pyrosequencing were evaluated regarding
the conservation of the affected amino acid across several species. RNASE III
protein sequences from Homo sapiens (NP_037367.3), Danio rerio
(NP_001103942.1), Drosophila melanogaster (NP_477436.1), Caenorhabditis
elegans (AAD45518.1) and E. coli (YP_490795.1) were aligned using CLCBio
Genomics Workbench Software (CLCBio) (Fig. 1a).
Gene panel parallel sequencing. We designed an Ion AmpliSeq panel using the
Ion AmpliSeq Designer v3.0.1 (Life Technologies). The panel was composed of 16
genes: 10 core genes of the miRNA-processing pathway (DROSHA, DGCR8, RAN,
XPO5, DICER1, TARBP2, AGO1, AGO2, GEMIN4 and DDX20) and 6 genes
previously reported as somatically mutated in WT (WT1, CTNNB1, WTX, TP53,
DIS3L2 and FBXW7 (refs 8,11–18), corresponding to a total of 59.81 kb. Libraries
were prepared for 66 fresh-frozen samples using 20 ng of DNA from each sample
according to the Ion AmpliSeq Library Preparation protocol. Template
preparation, emulsion PCR and Ion Sphere Particles enrichment were performed
using the Ion PGM Template OT2 200 kit (Life Technologies), according to the
manufacturer’s instructions. Sequencing was performed in an Ion PGM Sequencer
using an Ion 316 Chip and Ion PGM Sequencing 200 Kit v2 (Life Technologies). In
total, 3 sequencing runs were carried out, with a maximum of 32 samples per run.
Sequencing reads were quality-filtered and sorted according to barcodes using
Torrent Suite Browser 4.0.1. On average 154,060 reads (B155 pb) were mapped
against the human genome reference (hg19) per sample, of which 485% mapped
to the targeted region. The mean targeted base coverage depth was 280 (ranging
from 40 to 622 ). SNVs and indels were identified using the VariantCaller
v4.0.r73742 plugin from Torrent Suite Browser. References sequences used for
variant nomenclature were: DROSHA (NM_013235.4), DGCR8 (NM_022720.6),
DICER1 (NM_030621.3), XPO5 (NM_020750.2), TARBP2 (NM_004178.4),
CTNNB1 (NM_001904.3), WT1 (NM_000378.4), WTX (NM_152424.3),
TP53 (NM_000546.5), FBXW7 (NM_018315.4) and DIS3L2 (NM_152383.4).
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Variants were selected based on the following criteria: (a) minimum coverage
depth of 30 ; (b) minimum variant frequency of 5%; (c) only alterations leading
to amino-acid changes, splice site variants or premature stop codon were
considered; (d) variants were not present in dbSNP (release #139), except to those
with no minor allele frequency description (Table 1). All indel and nonsense
variants were selected for validation by capillary Sanger sequencing. Two DROSHA
nonsense variants were also validated by allele-specific PCR (primer sequences
used in this analysis are described in Supplementary Table 12). For missense
variants, Polyphen-2 (ref. 41), SIFT42 and MutationTaster43 classification tools
were used to determine the impact of amino-acid changes on protein function.
Taqman low-density arrays assays. TaqMan Array Human MicroRNA A Card
v1.0 microfluidics cards (Life Technologies) were used to assess the miRNA profiles
of 13 WT patient samples and transfected HEK293/HEK293T cells. In brief, 750 ng
of total RNA was used for miRNA cDNA synthesis using the TaqMan microRNA
Reverse Transcription Kit and Megaplex RT primers Human Pool A (both from
Life Technologies), following the manufacturer’s protocol. cDNA products were
then combined with TaqMan Universal Master Mix II with UNG (Life Technol-
ogies), and loaded into the microfluidics cards. Real-time PCR was performed on
the ABI PRISM 7900HT detection system (Applied Biosystems) according to the
manufacturer’s instructions.
The contents of the MicroRNA A Card comprised a total of 377 unique
miRNAs and three control small RNAs. In the tumours, 249 miRNAs were
evaluable in at least three samples (Cqr35) and were considered for the analysis.
In the cell lines, 187 and 179 miRNAs (Cqr35 in at least 40% of the extracts) were
considered for the analyses of transiently and stably transfected cells, respectively.
The array data were analysed using SDS software (Life Technologies), and miRNA
levels were normalized by the average of the four replicates of the mammalian U6
reference transcript using the 2 (delta)Cq method.
For tumour samples, relative expression differences between the two groups
were obtained by the ratio of the mean normalized values of the mutated to non-
mutated samples. miRNAs were considered differentially expressed between the
groups if the fold change was Z|2| and FDR-adjusted P-value r0.05 (Student’s
t-test). Volcano plots were generated using CLC Genomics Workbench 6.0.3
(CLCBio). Z-scores44 of log2-transformed expression values from the differentially
expressed miRNAs were used to perform unsupervised hierarchical clustering of
samples. Clustering was performed with TMEV (http://www.tm4.org/) using
Pearson’s correlation and average linkage.
For the transiently transfected cell lines, the regulation of miRNA expression of
each population of cells (mock, Drosha wild-type or Drosha-E1147K) during the
time course of the experiment was evaluated with STEM analysis (http://
www.cs.cmu.edu/Bjernst/stem/), using a fold change Z|2| as the parameter value
(a full explanation on STEM analysis is provided at the Supplementary Methods).
For the stably transfected cells, relative expression differences between the wild-
type Drosha and Drosha-E1147K cell lines were obtained by the ratio of the mean
normalized values of the four passages of E1147K cells by the wild-type cells.
miRNAs were considered differentially expressed between the groups if the fold
change wasZ|2| and FDR-adjusted P-valuer0.05 (Student’s t-test). Volcano plots
were generated using CLC Genomics Workbench 6.0.3 (CLCBio).
Taqman reverse-transcription qPCR. The expression of eight differentially
expressed and six control primary and mature miRNA pairs was assessed with
TaqMan individual assays (TaqMan Pri-miRNA Assays for pri-miRNAs and
TaqMan MicroRNA Assays for mature miRNAs—Life Technologies). Differen-
tially expressed miRNAs (miR-95, miR-128a, miR-135b, miR-874, miR-876-5p,
miR-126, miR-150 and miR-636) were selected based on FDR-adjusted P-value
(r0.05), fold change (r 3.45 or Z2.0) and the availability of commercial
pri-miRNA assays (taqman probes from Life Technologies). Among the non-
differently expressed miRNAs, we selected six with miRNAs assays available in our
lab (miR-26b, Let-7b, Let-7c, Let-7d, Let-7e and Let-7g) and used as controls.
Reverse transcriptase (RT)-qPCR was performed on an ABI PRISM 7900HT
detection system (Applied Biosystems) according to the manufacturer’s instruc-
tions. The relative expression levels of pri-miRNAs and miRNAs were calculated
using the 2–(delta)Cq method. Pri-miRNAs expressions were normalized by GAPDH
expression and miRNAs expressions were normalized by mammalian U6. Genes
were considered as differentially expressed between the groups if fold changes were
Z|2| and P-value r0.05 (Student’s t-test).
Cell culture and transfection of wild-type and E1147K-DROSHA. Human
embryonic kidney cell lines HEK293 and HEK293T were obtained from ATCC.
Cells were grown in Dulbecco’s modified Eagle’s medium (Invitrogen), supple-
mented with 2mM L-glutamine, 10% bovine fetal serum, 100Uml 1 penicillin
and 100mgml 1 streptomycin, in a humidified atmosphere at 37 C with 5% CO2.
For Drosha transfection assays, we used the pcDNA4/TO/cmycDrosha
plasmid27 (Addgene #10828) containing the wild-type Drosha sequence. To obtain
an E1147K DROSHA-expressing plasmid, we performed site-directed mutagenesis
using the QuikChange II-XL Site-Directed Mutagenesis Kit (Agilent Technologies).
PCR products were cloned into XL10-Gold Ultracompetent Cells using heat-shock
transformation. The presence of the mutation was confirmed on selected clone
inserts by capillary Sanger sequencing of the flanking region.
HEK293 cells were transfected in six-well plates at 90% confluent layer with
2.5 mg of wild-type DROSHA, E1147K DROSHA and mock plasmids using
Lipofectamine LTX Reagent (Life Technologies), according to the manufacturer’s
instructions. The transient transfections were performed twice in a 72-h interval,
and total RNA was extracted 48 h after the first transfection, 48 h after the second
transfection and 72 h after the second transfection. HEK293T cells were stably
transfected using the same conditions described for HEK293. After 24 h of
transfection, the medium was replaced with medium containing Zeocin
150 mgml 1 (Invitrogen). Selection was performed for 15 days.
Western blot. Western blotting was performed to detect the expression of
transfected wild-type and E1147K DROSHA in HEK293 and HEK293T cell lines.
Cell pellets were diluted in RIPA buffer with phosphatase inhibitor cocktail 3
(1:100, Sigma-Aldrich) and protease inhibitor cocktail (1:100, Sigma), and lysed by
temperature change (dry ice and 37 C repeated 10 ). Protein concentration was
quantified using the QuantiPRO BCA assay kit (Sigma-Aldrich), loaded onto an
SDS-PAGE gel (10%) and transferred onto polyvinylidene difluoride membrane.
The blots were probed with anti-myc-HRP (1:5,000, Invitrogen), anti-Drosha
(rabbit monoclonal, 1:1,000, Cell Signaling) and anti-GAPDH (mouse polyclonal,
1:1,000, Invitrogen) at 4 C overnight and subsequently incubated with horseradish
peroxidase-conjugated secondary antibody (1:3,000). Signals were visualized using
ECL Substrates (Millipore) and captured with UVItec Alliance 4.7 (UVItec)
(Supplementary Figs 5b, 7b and 8). For quantification of proteins bands, densi-
tometry was performed with ImageJ 1.4 (http://imagej.software.informer.com/1.4/).
SYBR Green qPCR. RT–qPCR was performed to confirm the expression of
transfected wild-type and E1147K DROSHA in HEK293/HEK293T cell lines.
Briefly, 1 mg total RNA was converted into cDNA in the presence of SuperScript III
RT (Invitrogen) and oligo(dT)18. Reactions were performed using cDNA con-
verted from 10 ng of RNA, 250 nM of each primer and 1 SYBR Green PCR
Master Mix (Life Technologies) in a total volume of 20 ml. Primers used for
DROSHA were as previously described45 (forward: 50-TAGGCTGTGGGAAA
GGACCAAG-30 ; reverse: 50-GTTCGATGAACCGCTTCTGATG-30). ACTB and
GAPDH were used for data normalization. Mock transfected cells were used as a
calibrator and relative fold changes were calculated using the 2–[delta][delta]Cq
method (Supplementary Figs 5c and 7c).
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